Plant defensin PvD₁ modulates the membrane composition of breast tumour-derived exosomes

Abstract

Plant defensin PvD1 attenuates recruitment of CD63 and CD9 to emerging exosomes of breast cancer MCF-7 cells, and binds to mature exosomes, which uncovers the nutraceutical potential of the natural source of PvD1, the bean Phaseolus vulgaris.

Electrostatic Surface Properties of Blood and Semen Extracellular Vesicles: Implications of Sialylation and HIV-Induced Changes on EV Internalization

“…Thus, understanding vesicular components that regulate cellular uptake, such as those demonstrated in this current manuscript, may have a positive impact on the drug delivery field. Furthermore, direct pharmacological manipulation of EV ζ-potential has also been shown to generate promising anti-cancer effects [ 104 ]. These examples, along with the results presented here, highlight the critical roles of the surface electrical charges of EV.…”

Antimicrobial peptides: mechanism of action, activity and clinical potential

“…Homozygous deletion of the θ-defensin gene in different cancers activates oncogenic pathways and suppresses immune response pathways [ 288 ], implicating its potential as a prognostic biomarker for immunotherapy. Treatment with the plant-derived natural defensin PvD1 in breast cancer cells inhibits tumor growth by modulating the exosomal membrane composition [ 289 ]. A novel frog skin-isolated peptide dermaseptin-PP exerts the anti-tumor activity in lung cancer cells by inducing cell apoptosis via both endogenous mitochondrial apoptosis pathway and exogenous death receptor apoptosis pathway [ 290 ].…”

The roles of exosomes in cancer drug resistance and its therapeutic application

“…As the critical biomarker of exosomes, the expression of CD9 and CD63 can be inhibited by plant defensin PvD1 in BC cells, subsequently affecting the formation of exosomes. PvD1 is able to bind to the mature exosomes in the extracellular environment as well, highlighting its potential therapeutic capability in antagonizing exosomes‐mediated malignant behaviors of cancer 83 . However, the study didn't elucidate the mechanism of the aberrant expression of CD9 and CD63 caused by PvD1.…”

“…PvD1 is able to bind to the mature exosomes in the extracellular environment as well, highlighting its potential therapeutic capability in antagonizing exosomes-mediated malignant behaviors of cancer. 83 However, the study didn't elucidate the mechanism of the aberrant expression of CD9 and CD63 caused by PvD1. In addition, bisindolylmaleimide-I or chloramidine can also significantly improve the efficacy of anti-tumor therapy by impeding the release of exosomes.…”